Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Media Coverage
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Media Coverage
Enveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds [Benzinga]
February 21, 2024
Non-Hallucinogenic Psilocybin-Based Therapies Promote Neuroplasticity Show Promise Treating Mental Health Disorders with Joe Tucker Enveric Biosciences [Empowered Patient Podcast]
February 12, 2024
Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders [ACS Publications]
January 29, 2024
The trends that will shape the biotech industry in 2024 [Labiotech]
January 25, 2024
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond [Benzinga]
January 10, 2024
Enveric’s EB-003 selected as lead candidate for mental health disorders [Pharmaceutical Technology]
December 29, 2023
Trip Or No Trip Pharmas Are Taking Psychedelic Trials To Australia [Clinical Leader]
December 13, 2023
The Path to Regulation of Psychedelic Therapies with Dr. Joe Tucker Enveric Biosciences [Digital Politics with Karen Jagoda]
December 6, 2023
Joseph Tucker – Drugs for Neuroplasticity [The Mindfulness Experience Podcast]
November 4, 2023
Psilocin prodrug receives USPTO development approval [Psychedelic Health]
November 2, 2023
‹
1
2
3
4
…
9
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact